Friday, November 6, 2015 

HALL A
 
  08:30-10:00
Screening and treating thrombophilia
Chairpersons Jean Christophe Gris, France
Aharon Lubetsky, Israel
 08:30-09:20
08:30
08:50
09:10
Debate:  Role of low molecular weight heparin in pregnancy complications:
Major: Jean-Christophe Gris, France
Minor: Benjamin Brenner, Israel 
Discussion
09:20-09:40
State of the Art: What is the role of thrombophilia in venous thromboembolism?
Aharon Lubetsky, 
Israel
09:40-09:50

The dominant antithrombin Budapest 3 mutation in the Hungarian population is caused by
a founder effect; genotype-phenotype relations investigated in a large cohort
Zsuzsanna Bereczky, Hungary

09:50-10:00

Inherited thrombophilia in women with unexplained recurrent pregnancy loss or idiopathic infertility: Reproductive friend or foe?
Valeria Raparelli, Italy


HALL A
 
10:30-11:40
Pharmacogenomics and thrombolytic therapy
Chairpersons Yosef Caraco, Israel
Emilio Clementi, Italy
 10:30-10:50
State of the Art: Catheter guided thrombolysis for deep vein thrombosis and pulmonary embolism
Alan Bloom, Israel
 10:50-11:40
10:50
11:10
11:30
Debate:  Pharmacogenomics in antithrombotic therapy
Advantages: Yosef Caraco, Israel
Limitations: Emilio Clementi, Italy
Discussion

HALL A
16:30-17:40
Antiplatelet treatment and its monitoring
Chairpersons

Marco Cattaneo, Italy
Giovanni Davì, Italy

16:30-17:20
16:30
16:50
17:10
Debate:  New antiplatelet agents
Advantages: Giovanni Davì, Italy
Limitations: Marco Cattaneo, Italy
Discussion
17:20-17:40
State of the Art: Monitoring antiplatelet therapy 
Marco CattaneoItaly

 

      HALL A
 

        17:40-18:00
 Immune thrombocytopenic purpura
        Chairperson:
David Varon, Israel
 
State of the Art: Thrombopoietins for immune thrombocytopenic purpura and beyond 
James Bussel, USA

Saturday, November 7, 2015 

HALL A  
08:30-10:30
New oral anticoagulants for the treatment of venous thromboembolism and atrial fibrillation
Chairpersons

Giancarlo Agnelli, Italy
Benjamin Brenner, Israel

08:30-09:20
08:30
08:50
09:10
Debate: New oral anticoagulants for treatment and prevention of venous thromboembolism
Advantages: Giancarlo Agnelli, Italy
Limitations: Aharon Lubetsky, Israel
Discussion
 09:20-10:10
09:20
09:40
10:00
Debate: New oral anticoagulants in cardiology
Advantages: Giovanni Davì, Italy
Limitations: Benjamin Brenner, Israel
Discussion
10:10-10:20 
“Real word” initial experience on safety and efficacy with Ticagrelor vs. Clopidogrel in acute coronary syndromes
Michel Butron-Calderon, Spain
 10:20-10:30

A risk score for prediction of recurrence in patients with unprovoked venousthromboembolism  (DAMOVES)
Ana Isabel Franco, Spain


HALL A  
14:00-15:40
Antithrombotics for patient subgroups
Chairpersons

Eduardo Arellano-Rodrigo, Spain
Pier M. Mannucci, Italy

 14:00-14:50
14:00
14:20
14:40
Debate: Anti thrombotics for atrial fibrillation (AF) in the oldest old
Vitamin K antagonists: Pier M. Mannucci, Italy
Direct oral anticoagulants: Paolo Prandoni, Italy
Discussion
 14:50-15:40
14:50
15:10
15:30
Debate: Secondary prophylaxis of thrombosis in myeloproliferative neoplasms
Yes: Eduardo Arellano-Rodrigo, Spain
No: Gunnar Birgegard, Sweden
Discussion

HALL A  
16:10-17:50
Prevention of venous thromboembolism and coronary artery disease
Chairpersons

Sergio Coccheri, Italy
Carlo Patrono, Italy

 16:10-17:00
16:10
16:30
16:50
Debate: Extended venous thromboembolism prophylaxis
Advantages: Paolo Prandoni, Italy
Limitations: Giancarlo Agnelli, Italy
Discussion
 17:00-17:50
17:00
17:20
17:40
Debate: Primary prevention with aspirin of coronary and cerobrovascular artery disease
Advantages: Carlo Patrono, Italy
Limitations: Sergio Coccheri, Italy
Discussion